Merger Updates, Milestone Payments, AGM Results, Review of Strategic Alternatives and Other Corporate Announcements - Research

     Merger Updates, Milestone Payments, AGM Results, Review of Strategic
 Alternatives and Other Corporate Announcements - Research Report on Cubist,
                     Halozyme, Taro, Galena and Sequenom

PR Newswire

NEW YORK, October 1, 2013

NEW YORK, October 1, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Investors' Reports announced new research reports highlighting Cubist
Pharmaceuticals Inc. (NASDAQ: CBST), Halozyme Therapeutics, Inc. (NASDAQ:
HALO), Taro Pharmaceutical Industries Ltd. (NYSE: TARO), Galena Biopharma,
Inc. (NASDAQ: GALE) and Sequenom Inc. (NASDAQ: SQNM). Today's readers may
access these reports free of charge - including full price targets, industry
analysis and analyst ratings - via the links below.

Cubist Pharmaceuticals Inc. Research Report

On September 13, 2013, Cubist Pharmaceuticals, Inc. (Cubist) and Optimer
Pharmaceuticals, Inc. (Optimer) announced the expiration of the waiting period
under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR).
According to Cubist, the expiration of the HSR waiting period meets one of the
conditions of the previously announced merger agreement under which Cubist
will acquire all of the outstanding common stock of Optimer. The Company
informed that, post-closing of the merger each holder of Optimer common stock
will receive $10.75 per share in cash, plus one Contingent Value Right which
entitles the holder to receive an additional one-time cash payment of up to
$5.00 for each share they own if certain net sales of DIFICID® (fidaxomicin)
in the United States and Canada are achieved. Cubist stated that the proposed
merger remains subject to approval by the stockholders of Optimer, as well as
other customary closing conditions. The Full Research Report on Cubist
Pharmaceuticals Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-26/CBST]

Halozyme Therapeutics, Inc. Research Report

On September 26, 2013, Halozyme Therapeutics Inc. (Halozyme) announced that
the commercial launch of Herceptin SC in Europe has sparked off a $10 million
milestone payment to Halozyme from Roche, under the License and Collaboration
Agreement between the duos. According to the Company, this time-saving
subcutaneous formulation of Herceptin (trastuzumab) using Halozyme's
recombinant human hyaluronidase (rHuPH20) has received marketing authorization
from the European Commission on August 28, 2013 for the treatment of patients
with HER2-positive breast cancer. "With pricing on par with the intravenous
formulation, Herceptin SC represents a compelling treatment alternative for
breast cancer patients in Europe, and we congratulate Roche on making this
time-saving therapy available to patients in Europe so quickly," said Gregory
I. Frost, Ph.D., President and CEO of Halozyme. "This will be the third
commercial product using our rHuPH20 enzyme and represents a significant
achievement for our technology and company as a whole." The Full Research
Report on Halozyme Therapeutics, Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.investorsreports.com/report/2013-09-26/HALO]

Taro Pharmaceutical Industries Ltd. Research Report 

On September 13, 2013, Taro Pharmaceutical Industries Ltd. (Taro) announced
results from its annual general meeting of shareholders, held on September 12,
2013 at Euro Park, Italy House, Yakum, Israel. The Company informed that as
per the voting results of its shareholders, certified and tabulated by IVS
Associates, Inc, five directors (Dilip Shanghvi, Kal Sundaram, Sudhir Valia,
James Kedrowski and Dov Pekelman) were re-elected to the Company's Board of
Directors to serve until the close of the next annual general meeting of
shareholders. Taro added that two External Directors, namely, Ilana Avidov Mor
and Dan Biran, were re-elected for three-year period, commencing from December
31, 2013. Additionally, the shareholders also approved the Company's
Compensation Policy in accordance with the requirements of the Israeli
Companies Law, 5759-1999, besides appointing Ziv Haft, Certified Public
Accountants (Israel), a BDO member firm, as the Company's independent auditors
until the close of the next annual general meeting of shareholders of Taro.
The Full Research Report on Taro Pharmaceutical Industries Ltd. - including
full detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investorsreports.com/report/2013-09-26/TARO]

Galena Biopharma, Inc. Research Report

On September 23, 2013, Galena Biopharma Inc. (Galena) announced the closing of
the exercise in full of the underwriters' option to purchase an additional 2.6
million shares of common stock of Galena. The Company informed that the net
proceeds to Galena from the offering, including from the exercise in full of
the over-allotment options, are expected to be c.$37.6 million, after
deducting underwriting discounts and commissions and estimated offering
expenses payable by Galena. The Company stated that it intends to use the
proceeds for the commercialization of its first commercial product, Abstral®
(fentanyl) Sublingual Tablets, and its ongoing Phase 3 NeuVax™ (nelipepimut-S)
PRESENT (Prevention of Recurrence in Early-Stage, Node-Positive Breast Cancer
with Low to Intermediate HER2 Expression with NeuVax Treatment) clinical trial
and other clinical trials of its product candidates, and general corporate
purposes. The Full Research Report on Galena Biopharma, Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.investorsreports.com/report/2013-09-26/GALE]

Sequenom Inc. Research Report

On September 23, 2013, Sequenom, Inc.'s (Sequenom) announced that its Board of
Directors has approved a review of potential strategic alternatives for its
Genetic Analysis business segment. The Company stated that it has retained
Jefferies LLC as its financial advisor to help in the evaluation of
alternatives. Sequenom informed that it does not plan to disclose or comment
on developments regarding the strategic alternatives review process until
further disclosure is deemed appropriate. The Full Research Report on Sequenom
Inc. - including full detailed breakdown, analyst ratings and price targets -
is available to download free of charge at:
[http://www.investorsreports.com/report/2013-09-26/SQNM]

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Namrata Maheshwari, a CFA charterholder. However, we
    are only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Namrata Maheshwari,
CFA, has only reviewed the information provided by Equity News Network in this
article or report according to the Procedures outlined by Equity News Network.
Equity News Network is not entitled to veto or interfere in the application of
such procedures by the outsourced provider to the articles, documents or
reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

http://www.InvestorsReports.com

SOURCE Investors' Reports

Contact: Media Contact: Kristi Saunders, +1-315-982-6420 (North America)
 
Press spacebar to pause and continue. Press esc to stop.